Our latest news and publications.
September 25, 2023

SpineThera SALIENT Clinical Trial Results to Be Presented at Upcoming 22nd Annual ASRA Pain Medicine Meeting

September 6, 2023

SpineThera Announces Breakthrough Market Research Results for SX600 in the Management of Sciatica Pain

SpineThera, Inc. announces groundbreaking market research indicating a potential 70% market adoption of its flagship investigational drug SX600.
December 7, 2022

SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Supporting the Potential for Best-In-Class Therapy

PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced promising results from its Phase 2 proof-of-concept trial, SALIENT, supporting advancing the SX600 clinical development program and the potential for SX600 to represent a meaningful advance in the management of radicular leg pain (sciatica).